Genomind supports NAMI’s mission to build better lives for people affected by mental illness
CHALFONT, PA – June 28, 2012 – Genomind will demonstrate support for the millions of Americans affected by mental illness by participating in the National Alliance on Mental Illness (NAMI) 2012 National Convention. This marks the second year Genomind is appearing at NAMI; last year the company gave a presentation on emerging technologies in mental health.
The theme of this year’s meeting is “Think, Learn and Live: Wellness, Resiliency and Recovery.” It is a message that resonates with Genomind since the company was founded with the ultimate goal of improving patients’ lives – particularly the lives of patients with difficult-to-treat psychiatric conditions. Its core product, the Genecept™ Assay, is a simple to use, saliva-based tool to inform clinician treatment decision-making for a range of psychiatric disorders, including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD.
“We are proud to support NAMI,” said Dr. Jay Lombard, chief scientific officer and co-founder of Genomind. “It is a wonderful organization that is devoted to helping improve the lives of the over 1 in 4 adults and 1 in 10 children across America affected by mental illness. We share NAMI’s commitment to bringing advancements in research to clinical practice and patients.”
The convention will be held at the Sheraton Seattle from June 27-30. Genomind will exhibit the Genecept Assay in Booth 206. For more information about this year’s convention, please visithttp://www.nami.org/template.cfm?section=convention.
NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness. NAMI advocates for access to services, treatment, supports and research and is steadfast in its commitment to raising awareness and building a community of hope. For more information, please visit http://www.nami.org/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at https://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind